Sessions

Changing the Cell Therapy Landscape with In-Vivo Therapies: Is this a Viable Alternative for Point of Care Therapeutics?
Achieving Best Practice in Quality Control and Assurance
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
Analytics, Data and IT Tech Solutions: An Overview of Best Practices and Technology
Moving Away from Viral Vectors: Alternative Clinical Delivery Solutions for Gene Therapy
Industry 4.0 Approaches Transforming Cell and Gene Therapy
Accelerating the Digitalisation Revolution in Cell and Gene Therapy Development
Viral Vector Development: Safe and Effective Viral Vectors for Therapeutic Success

Changing the Cell Therapy Landscape with In-Vivo Therapies: Is this a Viable Alternative for Point of Care Therapeutics?

28 Jan 2022
09:00
SPONSORED BY
Humacyte

09:00 Chairperson’s Opening
David Peritt, Founder & Chief Scientific Officer, Lupagen

09:05 Presentation 1
David Fontana, Chief Technology Officer, Umoja Pharma

09:20 Presentation 2
Senior Representative, Humacyte

09:35 Presentation 3
Dan Shelly, Vice President, Prescient Therapeutics

09:50 Presentation 4
Speaker TBD

10:05 Speaker Q&A and Panel Discussion

Speakers

David Fontana
Chief Business and Strategy Officer
Umoja Biopharma
Daniel Shelly
Vice President
Prescient Therapeutics